Boehringer Ingelheim

This study tests whether starting two kidney medications—vicadrostat and empagliflozin—at the same time is better than starting them one after the other in adults with chronic kidney disease at risk of worsening. About 416 participants will take the drugs daily for 3 months, with…

This early study tests a new daily pill (BI 1823911) for people with advanced solid tumors that have a KRAS G12C mutation, including lung, colorectal, pancreatic, and bile duct cancers. The study aims to find a safe dose and see if the drug, alone or with another KRAS-targeting d…

This study tests a new drug, BI 764532, combined with chemotherapy in adults with advanced small cell lung cancer that came back after prior treatment. The goal is to find a safe dose and see if the combination helps control the cancer. About 69 participants will receive the drug…

This study looks at the long-term safety of the cancer drug brigimadlin in adults with solid tumors who have already taken it for at least 4 cycles in a previous study. Participants take brigimadlin tablets once every 3 weeks at the study site. Doctors monitor their health, track…

This study tests whether survodutide, a weekly injection for weight loss, is safe for the heart in people who are overweight or obese and have heart or kidney disease. About 5,500 adults will receive either the drug or a placebo for up to 2 years, along with diet and exercise adv…

This study tests a new medicine called BI 3032950 in 45 adults with moderate to severe ulcerative colitis who haven't improved with other treatments. The treatment starts with an IV infusion every 4 weeks for 12 weeks, then switches to a shot under the skin every 4 weeks for up t…

This study tests a new daily pill, zongertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene change. About 428 adults who have not had prior treatment for their advanced cancer will be randomly assigned to receive…

This study tests whether survodutide, a new medicine, helps people with obesity burn more energy and fat compared to semaglutide. About 64 adults aged 18-65 with a BMI between 30 and 45 will receive weekly injections for several months. Researchers will measure energy use in a sp…

This study looks at the long-term safety and effectiveness of the drug spesolimab in people with generalized pustular psoriasis (GPP), a rare and severe skin condition. About 131 adults who completed a prior spesolimab trial will receive the drug for up to 252 weeks (almost 5 yea…

This study tests a new medicine called BI 764524 in 187 adults with moderate to severe diabetic retinopathy, a diabetes complication that can damage eyesight. Participants receive different numbers of eye injections over a year, and doctors compare their eye health to those getti…

This study looks at whether a daily pill called BI 1291583 is safe and helps control symptoms of bronchiectasis, a long-term lung condition. About 268 adults who were in earlier studies of this drug will take low, medium, or high doses for up to one year. Researchers will track s…

This study tests whether combining several drugs can shrink tumors in adults with head and neck cancer that has come back or spread. Participants receive up to three antibodies: two that help the immune system fight cancer, one that blocks tumor growth signals, and one that cuts …

This early-stage study tests a new medicine called BI 3000202 in 16 adults with rare immune disorders like Aicardi-Goutières syndrome. Participants take the drug as tablets for 40 weeks to see if it is safe and how the body processes it. The goal is to control the disease, not cu…

This study looks at the safety and effectiveness of taking JARDIANCE® tablets every day for a long time in people with chronic kidney disease. About 1,024 patients in Japan who are prescribed the drug for kidney disease will be followed in real-world settings. Researchers will tr…

This early-phase study tests a new experimental drug called BI 764532 (obrixtamig) combined with standard chemotherapy and immunotherapy for adults with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of BI 764532 when given with standard tr…

This study tests whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. About 42 adults with a history of GPP flares will receive a single infusion of spesolimab at the start of a flare, with…

This early-phase study tests a new experimental drug, BI 765179, in adults with advanced solid tumors or head and neck cancer that has not responded to standard treatments. The study has two parts: the first finds the safest dose of BI 765179 alone or with another drug (ezabenlim…

This study tests a new medicine called BI 771716 against an approved treatment (pegcetacoplan) for geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. About 202 adults aged 50 and older will receive eye injections every 4 weeks for ov…

This study tests an experimental drug (BI 765049) alone or with another drug (ezabenlimab) in Asian adults with advanced cancers like stomach, lung, pancreatic, colorectal, head and neck, or liver cancer. The goal is to find the highest safe dose and see if the drugs can shrink t…

This study looks at whether survodutide enters the body the same way when given by a pre-filled syringe or a pre-filled pen. About 56 healthy or overweight adults will receive one dose of each method and have blood samples taken. The goal is to see if the two delivery methods are…

This study follows 88 adults with connective tissue disease-related progressive lung scarring who are taking nintedanib. Researchers want to see if improvements in lung function match up with less coughing and easier breathing over 24 months. The goal is to better understand how …

This study tests whether a single dose of vicadrostat changes heart rhythm compared to a placebo. It involves 45 healthy adults aged 18 to 50. The goal is to check for any heart-related side effects, not to treat a disease.

This study tests a new formulation of survodutide, a medicine being developed for obesity and liver conditions. About 100 healthy adults aged 18 to 65 with a BMI between 27 and 40 will receive either the current or new formulation once a week for about 6.5 months. Researchers wil…

This study follows 157 adults with pulmonary fibrosis who are taking nintedanib and enrolled in a patient support program in Spain. Researchers will measure how satisfied patients are with the program and monitor their quality of life, depression symptoms, and side effects over 1…

This study examines how over 547,000 people in France use SGLT2i drugs for type 2 diabetes. Researchers will look at patient characteristics, prescription patterns, and track heart, kidney, and safety events. The goal is to understand real-world use and outcomes, not to test a ne…

This early-phase study involves 14 adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Researchers use PET/CT scans to track where two experimental drugs (BI 765063 and BI 770371) go in the body and how much they reach tumors. Part…

This study looks at whether the heart-protective effects of the diabetes drug empagliflozin, seen in earlier clinical trials, also happen in a much larger, more diverse group of patients in real-world settings. Researchers will analyze health records from over 200,000 adults with…

This study examines whether SGLT2 inhibitors, a type of diabetes drug, can delay or prevent anemia in people with chronic kidney disease. Researchers will compare 15,000 patients who take these drugs with those who don't, tracking lab results, treatments, and costs over two years…

This study looks at medical records of nearly 8,000 people with HER2-altered metastatic breast cancer in the United States. Researchers want to see what treatments patients actually receive and how long they live. The goal is to understand real-world care patterns, not to test a …

This study follows 2,000 people with systemic sclerosis (scleroderma) who have lung scarring (interstitial lung disease) and are taking nintedanib. Researchers want to see how the drug affects lung function, quality of life, and survival over time. Participants are already part o…